Miller T, Cudkowicz M, Shaw PJ et al (2020) Phase 1–2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 383:109–119
Article CAS PubMed Google Scholar
Mueller C, Berry JD, McKenna-Yasek DM et al (2020) SOD1 suppression with adeno-associated virus and microRNA in familial ALS. N Engl J Med 383:151–158
Article CAS PubMed Google Scholar
Omer T, Finegan E, Hutchinson S et al (2017) Neuroimaging patterns along the ALS-FTD spectrum: a multiparametric imaging study. Amyotroph Lateral Scler Frontotemporal Degener 18:611–623
Article CAS PubMed Google Scholar
Burke T, Pinto-Grau M, Lonergan K et al (2017) A Cross-sectional population-based investigation into behavioral change in amyotrophic lateral sclerosis: subphenotypes, staging, cognitive predictors, and survival. Ann Clin Transl Neurol 4:305–317
Article PubMed PubMed Central Google Scholar
Finegan E, Chipika RH, Shing SLH, Hardiman O, Bede P (2019) Primary lateral sclerosis: a distinct entity or part of the ALS spectrum? Amyotroph Lateral Scler Frontotemporal Degener 20:133–145
Burke T, Elamin M, Bede P et al (2016) Discordant performance on the “reading the mind in the eyes” test, based on disease onset in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 17:467–472
Article CAS PubMed Google Scholar
Kiernan MC, Ziemann U, Eisen A (2019) Amyotrophic lateral sclerosis: origins traced to impaired balance between neural excitation and inhibition in the neonatal period. Muscle Nerve 60:232–235
Bertrand A, Wen J, Rinaldi D et al (2018) Early cognitive, structural, and microstructural changes in presymptomatic C9orf72 carriers younger than 40 years. JAMA Neurol 75:236–245
Querin G, Bede P, El Mendili MM et al (2019) Presymptomatic spinal cord pathology in c9orf72 mutation carriers: a longitudinal neuroimaging study. Ann Neurol 86:158–167
Article CAS PubMed Google Scholar
Cirak S, Arechavala-Gomeza V, Guglieri M et al (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378:595–605
Article CAS PubMed PubMed Central Google Scholar
Mendell JR, Rodino-Klapac LR, Sahenk Z et al (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74:637–647
Article CAS PubMed Google Scholar
Mendell JR, Goemans N, Lowes LP et al (2016) Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 79:257–271
Article CAS PubMed PubMed Central Google Scholar
Lee SE, Sias AC, Mandelli ML et al (2017) Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. Neuroimage Clin 14:286–297
Walhout R, Schmidt R, Westeneng HJ et al (2015) Brain morphologic changes in asymptomatic C9orf72 repeat expansion carriers. Neurology 85:1780–1788
Article CAS PubMed Google Scholar
Le Blanc G, Jetté Pomerleau V, McCarthy J et al (2020) Faster cortical thinning and surface area loss in presymptomatic and symptomatic C9orf72 repeat expansion adult carriers. Ann Neurol 2:2
Papma JM, Jiskoot LC, Panman JL et al (2017) Cognition and gray and white matter characteristics of presymptomatic C9orf72 repeat expansion. Neurology 89:1256–1264
Lulé DE, Müller HP, Finsel J et al (2020) Deficits in verbal fluency in presymptomatic C9orf72 mutation gene carriers-a developmental disorder. J Neurol Neurosurg Psychiatry 91:1195–1200
Wen J, Zhang H, Alexander DC et al (2019) Neurite density is reduced in the presymptomatic phase of C9orf72 disease. J Neurol Neurosurg Psychiatry 90:387–394
De Vocht J, Blommaert J, Devrome M et al (2020) Use of multimodal imaging and clinical biomarkers in presymptomatic carriers of C9orf72 repeat expansion. JAMA Neurol 77:1–10
Article PubMed Central Google Scholar
Babić Leko M, Župunski V, Kirincich J et al (2019) Molecular mechanisms of neurodegeneration related to C9orf72 hexanucleotide repeat expansion. Behav Neurol 2019:2909168
Article PubMed PubMed Central Google Scholar
Balendra R, Isaacs AM (2018) C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol 14:544–558
Article CAS PubMed PubMed Central Google Scholar
Ng MC, Ho JT, Ho SL et al (2008) Abnormal diffusion tensor in nonsymptomatic familial amyotrophic lateral sclerosis with a causative superoxide dismutase 1 mutation. J Magn Reson Imaging 27:8–13
Carew JD, Nair G, Andersen PM et al (2011) Presymptomatic spinal cord neurometabolic findings in SOD1-positive people at risk for familial ALS. Neurology 77:1370–1375
Article CAS PubMed PubMed Central Google Scholar
Turner MR, Hammers A, Al-Chalabi A et al (2005) Distinct cerebral lesions in sporadic and “D90A” SOD1 ALS: studies with [11C]flumazenil PET. Brain 128:1323–1329
Article CAS PubMed Google Scholar
Panman JL, Jiskoot LC, Bouts M et al (2019) Gray and white matter changes in presymptomatic genetic frontotemporal dementia: a longitudinal MRI study. Neurobiol Aging 76:115–124
Rohrer JD, Nicholas JM, Cash DM et al (2015) Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol 14:253–262
Article PubMed PubMed Central Google Scholar
Olney NT, Ong E, Goh SM et al (2020) Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimers Dement 16:49–59
Article PubMed PubMed Central Google Scholar
Cash DM, Bocchetta M, Thomas DL et al (2018) Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiol Aging 62:191–196
Article PubMed PubMed Central Google Scholar
Diehl-Schmid J, Licata A, Goldhardt O et al (2019) FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. Transl Psychiatry 9:54
Article PubMed PubMed Central Google Scholar
Malpetti M, Holland N, Jones PS et al (2021) Synaptic density in carriers of C9orf72 mutations: a [(11) C]UCB-J PET study. Ann Clin Transl Neurol 8:1515–1523
Article CAS PubMed PubMed Central Google Scholar
van Veenhuijzen K, Westeneng HJ, Tan HHG et al (2022) Longitudinal effects of asymptomatic C9orf72 carriership on brain morphology. Ann Neurol 2:2
Shoukry RS, Waugh R, Bartlett D, Raitcheva D, Floeter MK (2020) Longitudinal changes in resting state networks in early presymptomatic carriers of C9orf72 expansions. Neuroimage Clin 28:102354
Article PubMed PubMed Central Google Scholar
Bonelli RM, Cummings JL (2007) Frontal-subcortical circuitry and behavior. Dialog Clin Neurosci 9:141–151
Lule D, Diekmann V, Muller HP, Kassubek J, Ludolph AC, Birbaumer N (2010) Neuroimaging of multimodal sensory stimulation in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 81:899–906
McKenna MC, Lope J, Bede P, Tan EL (2023) Thalamic pathology in frontotemporal dementia: predilection for specific nuclei, phenotype-specific signatures, clinical correlates, and practical relevance. Brain Behav. 2:e2881
McKenna MC, Li Hi Shing S, Murad A et al (2022) Focal thalamus pathology in frontotemporal dementia: phenotype-associated thalamic profiles. J Neurol Sci 436:120221
Chipika RH, Christidi F, Finegan E et al (2020) Amygdala pathology in amyotrophic lateral sclerosis and primary lateral sclerosis. J Neurol Sci 417:117039
Article CAS PubMed Google Scholar
Pinkhardt EH, van Elst LT, Ludolph AC, Kassubek J (2006) Amygdala size in amyotrophic lateral sclerosis without dementia: an in vivo study using MRI volumetry. BMC Neurol 6:48
Article PubMed PubMed Central Google Scholar
Chipika RH, Siah WF, Shing SLH et al (2020) MRI data confirm the selective involvement of thalamic and amygdalar nuclei in amyotrophic lateral sclerosis and primary lateral sclerosis. Data Brief 2:106246
Christidi F, Karavasilis E, Rentzos M et al (2019) Hippocampal pathology in amyotrophic lateral sclerosis: selective vulnerability of subfields and their associated projections. Neurobiol Aging 84:178–188
留言 (0)